tetano
Editor, Senior Moderator
Front Immunol. 2018 Jul 10;9:1547. doi: 10.3389/fimmu.2018.01547. eCollection 2018.
[h=1]Advancements in Host-Based Interventions for Influenza Treatment.[/h] Yip TF[SUP]1[/SUP], Selim ASM[SUP]1[/SUP], Lian I[SUP]2[/SUP], Lee SM[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a major acute respiratory infection that causes mortality and morbidity worldwide. Two classes of conventional antivirals, M2 ion channel blockers and neuraminidase inhibitors, are mainstays in managing influenza disease to lessen symptoms while minimizing hospitalization and death in patients with severe influenza. However, the development of viral resistance to both drug classes has become a major public health concern. Vaccines are prophylaxis mainstays but are limited in efficacy due to the difficulty in matching predicted dominant viral strains to circulating strains. As such, other potential interventions are being explored. Since viruses rely on host cellular functions to replicate, recent therapeutic developments focus on targeting host factors involved in virus replication. Besides controlling virus replication, potential targets for drug development include controlling virus-induced host immune responses such as the recently suggested involvement of innate lymphoid cells and NADPH oxidases in influenza virus pathogenesis and immune cell metabolism. In this review, we will discuss the advancements in novel host-based interventions for treating influenza disease.
[h=4]KEYWORDS:[/h] cytokines; host factors; immunomodulation; influenza; metabolism
PMID: 30042762 PMCID: PMC6048202 DOI: 10.3389/fimmu.2018.01547
Free full text
[h=1]Advancements in Host-Based Interventions for Influenza Treatment.[/h] Yip TF[SUP]1[/SUP], Selim ASM[SUP]1[/SUP], Lian I[SUP]2[/SUP], Lee SM[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is a major acute respiratory infection that causes mortality and morbidity worldwide. Two classes of conventional antivirals, M2 ion channel blockers and neuraminidase inhibitors, are mainstays in managing influenza disease to lessen symptoms while minimizing hospitalization and death in patients with severe influenza. However, the development of viral resistance to both drug classes has become a major public health concern. Vaccines are prophylaxis mainstays but are limited in efficacy due to the difficulty in matching predicted dominant viral strains to circulating strains. As such, other potential interventions are being explored. Since viruses rely on host cellular functions to replicate, recent therapeutic developments focus on targeting host factors involved in virus replication. Besides controlling virus replication, potential targets for drug development include controlling virus-induced host immune responses such as the recently suggested involvement of innate lymphoid cells and NADPH oxidases in influenza virus pathogenesis and immune cell metabolism. In this review, we will discuss the advancements in novel host-based interventions for treating influenza disease.
[h=4]KEYWORDS:[/h] cytokines; host factors; immunomodulation; influenza; metabolism
PMID: 30042762 PMCID: PMC6048202 DOI: 10.3389/fimmu.2018.01547
Free full text